Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Five Prime Therapeutics Inc. Shares Surged

By Sean Williams - Mar 17, 2014 at 1:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Five Prime lands a collaborative deal with a pharmaceutical giant. Find out what this new deal entails and how Five Prime will benefit.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Five Prime Therapeutics ( FPRX ), a clinical-stage biopharmaceutical company focused on developing protein therapeutics to fight cancer and other inflammatory diseases, jumped as much as 22% after announcing a collaborative deal with Bristol-Myers Squibb ( BMY 3.54% ) before the opening bell.

So what: Under the terms of the deal, Bristol-Myers Squibb gets access to Five Prime Therapeutics' exclusive immuno-oncology platform and will decipher which therapies have the best chance of success based on two undisclosed immune checkpoint pathways. Bristol-Myers has the option of developing these cancer-fighting drugs as a single-agent therapies or can use them in combination with existing products in its own pipeline. Bristol-Myers will retain full worldwide rights to these therapies if approved.

For Five Prime, the company will receive a $20 million upfront payment from Bristol-Myers, is eligible to receive $9.5 million in researching funding over the course of its collaboration, and is getting a $21 million common equity investment from Bristol-Myers (representing a purchase of 4.9% of Five Prime's outstanding shares) at a 30% premium to Friday's closing price. In addition, it will also be eligible to receive milestone and development payments totaling as much as $300 million and tiered single-digit to double-digit royalties on any approved therapies.

Now what: Once again we see how incredibly hot cancer immunotherapies have become. A number of cancer-focused companies are realizing that it's easier to retrain the body's immune system to recognize cancer and attack it than to attempt to formulate a therapy designed to seek out cancer. It remains to be seen, of course, if this partnership will merit success, but Five Prime shareholders have to be pleased to have snagged an elephant in Bristol-Myers Squibb, which could go a long way to validating its proprietary drug discovery platform. From the standpoint of Bristol-Myers, it allows the company to potentially expand its immunotherapeutic research for a mere $50.5 million in costs, so it seems well worth the risk.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Five Prime Therapeutics, Inc. Stock Quote
Five Prime Therapeutics, Inc.
FPRX
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$55.53 (3.54%) $1.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.